Sign in with your email address username.

×

[Comment] ICON-6: the danger of changing study design midstream

Jonathan Ledermann and colleagues1,2 report the ICON-6 randomised trial findings for the tyrosine kinase inhibitor cediranib in relapsed platinum-sensitive ovarian cancer. Cediranib offered the prospect of improved efficacy with tolerable side-effects, and ICON-6 was a pragmatic trial to provide real-world evidence of the effectiveness, safety, and acceptability of cediranib plus chemotherapy (either concurrent or concurrent plus maintenance as long as patients were deriving benefit), compared with chemotherapy plus placebo.

email